By Fineline Cube 
Shanghai-based biotech EpimAb Biotherapeutics announced a global licensing agreement with US-headquartered Juri Biosciences, Inc., a portfolio company of TCG Labs Soleil. The deal grants Juri exclusive global rights to a development-ready T-cell engager targeting kallikrein-related peptidase 2 (KLK2) and CD3 for the treatment of metastatic prostate cancer.
Financial Terms
Under the agreement, EpimAb is eligible to receive up to USD 210 million in payments. This includes an upfront payment and milestone payments tied to development, regulatory, and commercial events. Additionally, EpimAb will receive tiered royalties on future sales.
Scientific Advisory
Dr. Charles Sawyers, the inaugural Director of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, will serve as a strategic scientific advisor. He will collaborate closely with the TCG Labs Soleil team to support the program and guide the advancement of KLK2-directed therapies.
Preclinical Research
The T-cell engager, developed by EpimAb Biotherapeutics, has shown promising results in preclinical studies. It is designed to treat metastatic prostate cancer by engaging CD3 on T-cells and KLK2 on tumor cells, thereby enabling targeted immune response against cancer cells.-Fineline Info & Tech